Impact Factor
3.18
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.38
381 total citations
h5-index
19
h5 depth signal
Cited share
75.4%
126 of 167
Total citations
381
Citation footprint
Metric signal
2.18
External metric anchor
Self-citation
0.8%
3 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
200
Italy
141
Turkey
93
United States
57
Japan
48
Citing Fields of Research
Antibiotic & Antibacterial Agents
316
Oncology
122
Lung Cancer
73
Bacteriology
62
Cancer Drugs
56
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,663
Articles tracked across the journal lifetime
Indexed publication set
167
126 cited publications
Last 12 months
62
5.2 publications/month
Open access share
8.1%
5 OA publications in the last year
Leading citing country
China
200 citing publications
Leading citing field
Antibiotic & Antibacterial Agents
316 citing publications
Latest tracked publication
4 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1989-
v1n1, 1989-
Active Coverage
Research Focus & Classification
Indexed Subjects
Antibiotic & Antibacterial Agents
Oncology
Lung Cancer
Immunology
Breast Cancer
Cancer Drugs
Issuing & Sponsoring Bodies
Contributor
Mediterranean Society of Chemotherapy
Contributor
Mediterranean Society of Therapy
Contributor
Società italiana di chemioterapia
Broad Categories
Anti-Infective Agents
Antineoplastic Agents
Antibiotic & Antibacterial Agents
Immunology
Noncoding RNA
Cancer, Autophagy & Apoptosis
Lymphomas
Fungal Pathogenesis
Cancer Drugs
MeSH Descriptors
Anti-Infective Agents
Drug Therapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/1120009x.2026.2739728
Open DOI
Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance – a review
02
03
04
DOI 10.1080/1120009x.2026.2729966
Open DOI
Circular RNAs: key regulators and mechanistic insights in breast cancer drug resistance
05
DOI 10.1080/1120009x.2026.2728432
Open DOI
Tumor resistance to protein kinase inhibitors
Cancer treatment is difficult, there are many issues regarding cancer treatment because Protein Kinase Inhibitors (PKIs) are unable to control tumors that are resistant to them. Resistance to drugs starts with changes in genetic code and...
06
DOI 10.1080/1120009x.2026.2727267
Open DOI
First-line therapy and maintenance outcomes in Chinese patients with marginal zone lymphoma: a multicenter retrospective analysis with prognostic implications for chemotherapy decision-making
Marginal zone lymphoma (MZL) is a heterogeneous group of indolent B-cell non-Hodgkin lymphomas originating from post-germinal center B cells [1]. It accounts for approximately 5–17% of all non-Hodg...
07
DOI 10.1080/1120009x.2026.2722741
Open DOI
The epigenetic regulator ALKBH5 facilitates the early adaptation of hepatocellular carcinoma cells to sorafenib treatment
Hepatocellular carcinoma is still a significant cause of cancer deaths worldwide [1]. For patients with advanced stages, systemic therapy is a key treatment approach. Multi-targeted TKIs, such as s...
08
DOI 10.1080/1120009x.2026.2722740
Open DOI
Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy
According to Global Cancer Statistics 2020, esophageal cancer ranks seventh in age-standardized incidence and sixth in mortality worldwide [1]. As a high-incidence region, China reported 224,000 ne...
09
DOI 10.1080/1120009x.2026.2718574
Open DOI
The emerging trends in prostate cancer treatment: a systematic review of the literature
Prostate cancer remains the second most commonly diagnosed cancer in men worldwide, with an estimated 1.4 million new cases and 375,000 deaths annually [1]. The fundamental role of AR signaling in ...
10
DOI 10.1080/1120009x.2026.2717469
Open DOI
Six-month progression-free survival-related tumor growth rate after upfront chemotherapy as an outcome measure and potential prognostic or stratification variable for patients with unresectable pancreatic adenocarcinoma: an exploratory study cohorts analysis
Pancreatic adenocarcinoma ranks among the deadliest malignancies worldwide. In 2020, it was the seventh leading cause of cancer death in both men and women and, due to its poor prognosis, it caused...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Official organ of: the Mediterranean Society of Chemotherapy.
Official journal of: the Mediterranean Society of Therapy.
Published under the auspices of the Italian Society of Chemotherapy.